In the Cuban province of Matanzas, a clinical trial has begun for the drug Jusvinza, developed by the Center for Genetic Engineering and Biotechnology (CIGB). The medication targets residual polyarthritis in patients recovering from chikungunya. This step represents progress in local healthcare efforts.
A clinical trial for the drug Jusvinza has started in Cuba's Matanzas province, as reported by Prensa Latina on December 3, 2025. Developed by the Center for Genetic Engineering and Biotechnology (CIGB), Jusvinza aims to treat residual polyarthritis in patients recovering from chikungunya, a mosquito-borne illness.
This initiative highlights Cuba's ongoing work in biotechnology to address complications from infectious diseases. The trial marks a crucial phase in evaluating the drug's effectiveness and safety in practical settings. Matanzas, with its history of supporting medical research on the island, hosts this study.
While initial details focus on the trial's launch, future outcomes are anticipated to provide insights into its benefits for patients' quality of life. The effort aligns with the CIGB's record of producing accessible pharmaceutical innovations.